Pharvaris NV PHVS.OQ PHVS.O is expected to show no change in quarterly revenue when it reports results on April 8 (estimated) for the period ending December 31 2024
LSEG's mean analyst estimate for Pharvaris NV is for a loss of 72 cents per share.
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 7 "strong buy" or "buy," no "hold" and 1 "sell" or "strong sell."
The mean earnings estimate of analysts was unchanged in the last three months.
Wall Street's median 12-month price target for Pharvaris NV is $32.50, above its last closing price of $14.62.
Previous quarterly performance (using preferred earnings measure in euros).
QUARTER ENDING | STARMINESMARTESTIMATE® | LSEG IBES ESTIMATE | ACTUAL | BEAT, MET, MISSED | SURPRISE % |
Sep. 30 2024 | -0.62 | -0.61 | -0.77 | Missed | -26.1 |
Jun. 30 2024 | -0.55 | -0.55 | -0.55 | Met | 0.5 |
Mar. 31 2024 | -0.56 | -0.56 | -0.52 | Beat | 7.7 |
Dec. 31 2023 | -0.37 | -0.53 | -0.76 | Missed | -42.5 |
Sep. 30 2023 | -0.59 | -0.60 | -0.58 | Beat | 3.4 |
Jun. 30 2023 | -0.59 | -0.65 | -0.63 | Beat | 3.1 |
Mar. 31 2023 | -0.74 | -0.74 | -0.67 | Beat | 9.9 |
Dec. 31 2022 | -0.68 | -0.65 | -1.17 | Missed | -79.4 |
This summary was machine generated April 4 at 20:29 GMT. All figures in euros unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。